Profound Medical Corp.
PROF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 2.90 | 0.99 | -0.37 |
| FCF Yield | -12.61% | -12.57% | -11.37% | -9.99% |
| EV / EBITDA | -5.32 | -6.03 | -7.09 | -5.73 |
| Quality | ||||
| ROIC | -47.93% | -71.31% | -53.20% | -36.73% |
| Gross Margin | 65.89% | 60.87% | 45.22% | 42.95% |
| Cash Conversion Ratio | 0.84 | 0.80 | 0.90 | 0.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 15.02% | 1.56% | -2.93% | 18.09% |
| Free Cash Flow Growth | -3.73% | 12.37% | -12.40% | -9.70% |
| Safety | ||||
| Net Debt / EBITDA | 1.95 | 0.69 | 1.44 | 2.29 |
| Interest Coverage | 0.00 | -37.16 | -192.25 | -456.12 |
| Efficiency | ||||
| Inventory Turnover | 0.60 | 0.40 | 0.46 | 0.53 |
| Cash Conversion Cycle | 724.83 | 1,163.00 | 935.77 | 468.39 |